Post-COVID increase in N-methyl-2-pyridone-5-carboxamide (Met2PY) and N-methyl-4-pyridone-3-carboxamide (Met4PY) associates with inflammatory and endothelial activation markers
- 7 April 2026
- journal article
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 45 (11) , 1-14
Abstract
COVID-19 is associated with long-term vascular complications, but the underlying mechanisms remain incompletely understood. During infection, NAD+ homeostasis becomes dys-regulated, with excessive NAD+ consumption and enhanced catabolic flux through nicotinamide methylation pathways. This imbalance leads to NAD+ depletion accompanied by accumulation of pyridone metabolites, including N-methyl-2-pyridone-5-carboxamide (Met2PY) and N-methyl-4-pyridone-3-carboxamide (Met4PY). These derivatives have been linked to oxidative stress, endothelial dysfunction, and cardiovascular risk, yet their role in long COVID remains unclear. We enrolled 26 post-COVID patients with persistent cardiovascular symptoms and 8 healthy controls. Serum concentrations of Met2PY and Met4PY were quantified by LC/MS. High-sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNFα), interleukin-10 (IL-10), and soluble intercellular adhesion molecule-1 (sICAM-1) were measured to assess systemic inflammation and endothelial activation. Statistical analyses included group comparisons and correlation analyses. We observed significantly elevated Met2PY levels (0.770 ± 0.08 vs. 0.389 ± 0.09 µmol/l) and a trend toward increased Met4PY (0.095 ± 0.01 vs. 0.055 ± 0.01 µmol/l) in post-COVID patients compared with controls. Both metabolites positively correlated with hsCRP. Importantly, Met2PY was associated with an unfavorable cytokine profile (higher TNFα/IL-10 ratio) and increased sICAM-1 levels, whereas no such associations were observed for Met4PY. Persistent dysregulation of NAD+ metabolism and accumulation of pyridone metabolites, particularly Met2PY, are associated with markers of chronic endothelial activation and inflammation in long COVID. These findings support the potential utility of Met2PY as a biomarker to identify patients at higher risk for endothelial dysfunction and cardiovascular events, enabling more personalized risk stratification and follow-up.Keywords
Funding Information
- Polish Ministry of Science and Higher Education “Excellence Initiative – Research University” ((71-01428/K03-0009804/256))
This publication has 35 references indexed in Scilit:
- SIRT1: A likely key for future therapeutic strategies for pain managementPharmacological Research, 2025
- Follow-up assessment of the microvascular function in patients with long COVIDMicrovascular Research, 2024
- NAD+ metabolism and therapeutic strategies in cardiovascular diseasesAtherosclerosis Plus, 2024
- The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVIDSignal Transduction and Targeted Therapy, 2023
- Long COVID: major findings, mechanisms and recommendationsNature Reviews Microbiology, 2023
- COVID-19–Associated Endothelial Dysfunction and Microvascular InjuryCardiac Electrophysiology Clinics, 2021
- An unusual nicotinamide derivative, 4-pyridone-3-carboxamide ribonucleoside (4PYR), is a novel endothelial toxin and oncometaboliteExperimental & Molecular Medicine, 2021
- Nicotinamide N-methyltransferase in endothelium protects against oxidant stress-induced endothelial injuryBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2021
- COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activityMedical Hypotheses, 2020
- The age-related increase in N-methyl-2-pyridone-5-carboxamide (NAD catabolite) in human plasmaMolecular and Cellular Biochemistry, 2004